These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 25838513)

  • 21. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
    Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
    Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial.
    Ganeshalingam AA; Uhrenholt NG; Arnfred S; Gæde PH; Bilenberg N; Frystyk J
    BMJ Open; 2024 Mar; 14(3):e077173. PubMed ID: 38503415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study.
    Myat A; Arri S; Bhatt DL; Gersh BJ; Redwood SR; Marber MS
    Cardiovasc Diabetol; 2015 Feb; 14():27. PubMed ID: 25848859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
    Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liraglutide for treating type 1 diabetes.
    Dejgaard TF; Frandsen CS; Holst JJ; Madsbad S
    Expert Opin Biol Ther; 2016; 16(4):579-90. PubMed ID: 26926662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.
    Schmidt S; Frandsen CS; Dejgaard TF; Vistisen D; Halldórsson T; Olsen SF; Jensen JB; Madsbad S; Andersen HU; Nørgaard K
    Diabetes Obes Metab; 2022 Feb; 24(2):212-220. PubMed ID: 34595827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.
    Mensberg P; Nyby S; Jørgensen PG; Storgaard H; Jensen MT; Sivertsen J; Holst JJ; Kiens B; Richter EA; Knop FK; Vilsbøll T
    Diabetes Obes Metab; 2017 Feb; 19(2):172-180. PubMed ID: 27717126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI).
    Sprung VS; Kemp GJ; Wilding JP; Adams V; Murphy K; Burgess M; Emegbo S; Thomas M; Needham AJ; Weimken A; Schwab RJ; Manuel A; Craig SE; Cuthbertson DJ
    BMJ Open; 2020 Jul; 10(7):e038856. PubMed ID: 32699168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet.
    Jensen SBK; Lundgren JR; Janus C; Juhl CR; Olsen LM; Rosenkilde M; Holst JJ; Stallknecht BM; Madsbad S; Torekov SS
    BMJ Open; 2019 Nov; 9(11):e031431. PubMed ID: 31678947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study.
    Idorn T; Knop FK; Jørgensen M; Jensen T; Resuli M; Hansen PM; Christensen KB; Holst JJ; Hornum M; Feldt-Rasmussen B
    BMJ Open; 2013; 3(4):. PubMed ID: 23624993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.
    Dejgaard TF; Johansen NB; Frandsen CS; Asmar A; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Diabetes Obes Metab; 2017 May; 19(5):734-738. PubMed ID: 27935240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.
    Ishøy PL; Knop FK; Broberg BV; Baandrup L; Fagerlund B; Jørgensen NR; Andersen UB; Rostrup E; Glenthøj BY; Ebdrup BH
    BMJ Open; 2014 Jan; 4(1):e004158. PubMed ID: 24401727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
    Diabetes Res Clin Pract; 2017 Feb; 124():1-10. PubMed ID: 28086201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
    Davies MJ; Bain SC; Atkin SL; Rossing P; Scott D; Shamkhalova MS; Bosch-Traberg H; Syrén A; Umpierrez GE
    Diabetes Care; 2016 Feb; 39(2):222-30. PubMed ID: 26681713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
    Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).
    Sass MR; Danielsen AA; Köhler-Forsberg O; Storgaard H; Knop FK; Nielsen MØ; Sjödin AM; Mors O; Correll CU; Ekstrøm C; Vinberg M; Nielsen J; Vilsbøll T; Fink-Jensen A
    BMJ Open; 2023 Jan; 13(1):e068652. PubMed ID: 36720576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
    Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.